We harness the power of epigenetics
What we doCambridge Epigenetix is pioneering new sequencing and diagnostic tools to revolutionise cancer diagnosis and therapeutics, using the power of the 5-hydroxymethylcytosine (5hmC) epigenetic modification and the other epigenetic variants of 5-methylcytosine, alongside genetics..
Contact us
Epigenetics is vital
Why we do itOur proprietary discovery platform enables the identification of disease-specific hydroxymethylated (5hmC) DNA from blood and tissue samples — enhancing human health through more accurate and earlier diagnosis, improved patient stratification and the development of liquid biopsy-based tests.
Oncology
Cardiovascular
Neurology
Immunology
Reproductive HealthOur approach & capabilities
Partner and Pioneer
We focus on the 5hmC epigenetic modification and have a patent protected platform for detection of highly accurate signatures for a variety of diseases using this mark.
Research Tools
Developing proprietary technology to enhance epigenetics research.
Diagnostic Development
Delivering the next generation of diagnostic assays.
Therapeutics
Identifying novel therapeutic targets in collaboration with Pharma.
Disruptive technologies to improve human health
Our technologiesLearn moreInvesting in the future
Cambridge Epigenetix's pioneering work and unrivaled capabilities in harnessing epigenetic insights will unleash the potential of precision medicine.
Our Investors
